Role of P450 1A1 and P450 1A2 in Bioactivation versus Detoxication of the Renal Carcinogen Aristolochic Acid I: Studies in Cyp1a1(-/-), Cyp1a2(-/-), and Cyp1a1/1a2(-/-) Mice

被引:41
作者
Arlt, Volker M. [1 ,2 ]
Levova, Katerina [6 ]
Barta, Frantisek [6 ]
Shi, Zhanquan [3 ]
Evans, James D. [1 ,2 ]
Frei, Eva [4 ]
Schmeiser, Heinz H. [5 ]
Nebert, Daniel W. [3 ]
Phillips, David H. [1 ,2 ]
Stiborova, Marie [6 ]
机构
[1] Kings Coll London, Sch Biomed Sci, MRC HPA Ctr Environm & Hlth, London, England
[2] Inst Canc Res, Sect Mol Carcinogenesis, Surrey, England
[3] Univ Cincinnati, Med Ctr, Dept Environm Hlth, Cincinnati, OH USA
[4] German Canc Res Ctr, Natl Ctr Tumor Dis, Div Prevent Oncol, Heidelberg, Germany
[5] German Canc Res Ctr, Res Grp Genet Alterat Carcinogenesis, Heidelberg, Germany
[6] Charles Univ Prague, Dept Biochem, Prague, Czech Republic
基金
美国国家卫生研究院;
关键词
CHINESE HERBS NEPHROPATHY; BALKAN ENDEMIC NEPHROPATHY; HUMAN CYTOCHROMES P450; DNA ADDUCT FORMATION; ANTICANCER DRUG ELLIPTICINE; PROSTAGLANDIN-H SYNTHASE; METABOLIC-ACTIVATION; REDUCTIVE ACTIVATION; UROTHELIAL CANCER; GENE-EXPRESSION;
D O I
10.1021/tx200259y
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Exposure to aristolochic acid I (AAI) is associated with aristolochic acid nephropathy, Balkan endemic nephropathy, and urothelial cancer. Individual differences in xenobiotic-metabolizing enzyme activities are likely to be a reason for interindividual susceptibility to AA-induced disease. We evaluated the reductive activation and oxidative detoxication of AAI by cytochrome P450 (P450) 1A1 and 1A2 using the Cyp1a1(-/-) and Cyp1a2(-/-) single-knockout and Cyp1a1/1a2(-/-) double-knockout mouse lines. Incubations with hepatic microsomes were also carried out in vitro. P450 1A1 and 1A2 were found to (i) activate AAI to form DNA adducts and (ii) detoxicate it to 8-hydroxyaristolochic acid I (AAIa). AAI-DNA adduct formation was significantly higher in all tissues of Cyp1a1/1a2(-/-) than Cyp1a(+/+) wild-type (WT) mice. AAI-DNA adduct levels were elevated only in selected tissues from Cyp1a1 (-/-) versus Cyp1a2(-/-) mice, compared with those in WT mice. In hepatic microsomes, those from WT as well as Cyp1a1(-/-) and Cyp1a2(-/-) mice were able to detoxicate AAI to AAIa, whereas Cypla1/1a2(-/-) microsomes were less effective in catalyzing this reaction, confirming that both mouse P450 1A1 and 1A2 are both involved in AAI detoxication. Under hypoxic conditions, mouse P450 1A1 and 1A2 were capable of reducing AAI to form DNA adducts in hepatic microsomes; the major roles of P450 1A1 and 1A2 in AAI-DNA adduct formation were further confirmed using selective inhibitors. Our results suggest that, in addition to P450 1A1 and 1A2 expression levels in liver, in vivo oxygen concentration in specific tissues might affect the balance between AAI nitroreduction and demethylation, which in turn would influence tissue-specific toxicity or carcinogenicity.
引用
收藏
页码:1710 / 1719
页数:10
相关论文
共 56 条
  • [11] Aristolochic acid nephropathy: A worldwide problem
    Debelle, Frederic D.
    Vanherweghem, Jean-Louis
    Nortier, Joelle L.
    [J]. KIDNEY INTERNATIONAL, 2008, 74 (02) : 158 - 169
  • [12] Generation of 'humanized' hCYP1A1_1A2_Cyp1a1/1a2(-/-) mouse line
    Dragin, Nadine
    Uno, Shigeyuki
    Wang, Bin
    Dalton, Timothy P.
    Nebert, Daniel W.
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2007, 359 (03) : 635 - 642
  • [13] Aristolochic acid and the etiology of endemic (Balkan) nephropathy
    Grollman, Arthur P.
    Shibutani, Shinya
    Moriya, Masaaki
    Miller, Frederick
    Wu, Lin
    Moll, Ute
    Suzuki, Naomi
    Fernandes, Andrea
    Rosenquist, Thomas
    Medverec, Zvonimir
    Jakovina, Krunoslav
    Brdar, Branko
    Slade, Neda
    Turesky, Robert J.
    Goodenough, Angela K.
    Rieger, Robert
    Vukelic, Mato
    Jelakovic, Bojan
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (29) : 12129 - 12134
  • [14] Special Report: Policy A review of human carcinogens-Part A: pharmaceuticals
    Grosse, Yann
    Baan, Robert
    Straif, Kurt
    Secretan, Beatrice
    El Ghissassi, Fatiha
    Bouvard, Veronique
    Benbrahim-Tallaa, Lamia
    Guha, Neela
    Galichet, Laurent
    Cogliano, Vincent
    [J]. LANCET ONCOLOGY, 2009, 10 (01) : 13 - 14
  • [15] OXIDATION OF TOXIC AND CARCINOGENIC CHEMICALS BY HUMAN CYTOCHROME-P-450 ENZYMES
    GUENGERICH, FP
    SHIMADA, T
    [J]. CHEMICAL RESEARCH IN TOXICOLOGY, 1991, 4 (04) : 391 - 407
  • [16] Hypoxia - A key regulatory factor in tumour growth
    Harris, AL
    [J]. NATURE REVIEWS CANCER, 2002, 2 (01) : 38 - 47
  • [17] STUDIES ON THE METABOLISM OF ARISTOLOCHIC ACID-I AND ACID-II
    KRUMBIEGEL, G
    HALLENSLEBEN, J
    MENNICKE, WH
    RITTMANN, N
    ROTH, HJ
    [J]. XENOBIOTICA, 1987, 17 (08) : 981 - 991
  • [18] Kucab JE, 2010, FEBS J, V277, P2567, DOI [10.1111/j.1742-4658.2010.07676.x, 10.1111/j.1742-464X.2010.07676.x]
  • [19] Population-Based Case-Control Study of Chinese Herbal Products Containing Aristolochic Acid and Urinary Tract Cancer Risk
    Lai, Ming-Nan
    Wang, Shuo-Meng
    Chen, Pau-Chung
    Chen, Ya-Yin
    Wang, Jung-Der
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2010, 102 (03): : 179 - 186
  • [20] Late onset of bladder urothelial carcinoma after kidney transplantation for end-stage aristolochic acid nephropathy: A case series with 15-year follow-up
    Lemy, Anne
    Wissing, Karl M.
    Rorive, Sandrine
    Zlotta, Alexandre
    Roumeguere, Thierry
    Martinez, Marie-Carmen Muniz
    Decaestecker, Christine
    Salmon, Isabelle
    Abramowicz, Daniel
    Vanherweghem, Jean-Louis
    Nortier, Joelle
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2008, 51 (03) : 471 - 477